Purpose: To analytically and clinically validate a circulating cell-free tumor DNA sequencing
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …

Next-generation sequencing of cell-free circulating solid tumor DNA addresses two
challenges in contemporary cancer care. First this method of massively parallel and deep …

Purpose: Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow
noninvasive assessment of tumor biology, yet many existing assays are cumbersome and …

Background Approximately 30% of tumor biopsies from patients with advanced-stage lung
adenocarcinomas yield insufficient tissue for successful molecular subtyping. We have …

Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can
provide a noninvasive method for detecting genomic biomarkers to guide clinical decision …

Circulating tumor DNA (ctDNA) analysis is being incorporated into cancer care; notably in
profiling patients to guide treatment decisions. Responses to targeted therapies have been …

Tumor genomic instability and selective treatment pressures result in clonal disease
evolution; molecular stratification for molecularly targeted drug administration requires …

In current molecular cancer diagnostics, using blood samples of cancer patients for the
detection of genetic alterations in plasma (cell‐free) circulating tumor DNA (ct DNA) is an …

Genotyping tumor tissue in search of somatic genetic alterations for actionable information
has become routine practice in clinical oncology. Although these sequence alterations are …

Liquid biopsy by genotyping circulating tumor DNA (ctDNA) has provided a non-invasive
approach in assessing tumor genomic alterations in clinical oncology. However, emerging …